You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for SB 328437
SB 328437 is a potent and selective CCR3 antagonist (IC50 = 4 nM). Displays > 2500-fold selectivity over C5aR, LTD4, CCR7, CXCR1 and CXCR2 receptors. Inhibits eotaxin-, eotaxin-2- and MCP-4-induced Ca2+ mobilization (IC50 values are 38, 35 and 20 nM respectively) and inhibits eotaxin-, eotaxin-2- and MCP-4-induced eosinophil chemotaxis with similar potencies.
Compound Libraries for SB 328437
Technical Data for SB 328437
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SB 328437
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for SB 328437
The following data is based on the product molecular weight 378.38. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.64 mL||13.21 mL||26.43 mL|
|5 mM||0.53 mL||2.64 mL||5.29 mL|
|10 mM||0.26 mL||1.32 mL||2.64 mL|
|50 mM||0.05 mL||0.26 mL||0.53 mL|
References for SB 328437
References are publications that support the biological activity of the product.
White et al (2000) Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J.Biol.Chem. 275 36626 PMID: 10969084
Mori et al (2007) Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists. Int.Immunol. 19 913 PMID: 17804691
Abonyo et al (2005) Autoregulation of CCL26 synthesis and secretion in A549 cells: a possible mechanism by which alveolar epithelial cells modulate airway inflammation. Am.J.Physiol.Lung Cell.Mol.Physiol. 289 L478 PMID: 15863444
If you know of a relevant reference for SB 328437, please let us know.
View Related Products by Product Action
Keywords: SB 328437, SB 328437 supplier, SB328437, Potent, selective, CCR3, antagonists, chemokine, receptors, Rantes, Chemokine, CC, Receptors, 3650, Tocris Bioscience
2 Citations for SB 328437
Citations are publications that use Tocris products. Selected citations for SB 328437 include:
Christoph et al (2012) Graft-versus-host disease reduces regulatory T-cell migration into the tumour tissue. Immunology 137 80-8 PMID: 22681312
Jing et al (2020) Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma. Cell Death Dis 11 117 PMID: 32051393
Do you know of a great paper that uses SB 328437 from Tocris? Please let us know.
Reviews for SB 328437
There are currently no reviews for this product. Be the first to review SB 328437 and earn rewards!
Have you used SB 328437?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.